Bristol-Myers announces that the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer
- CheckMate -73L evaluated Opdivo (nivolumab) with concurrent chemoradiotherapy followed by Opdivo plus Yervoy(ipilimumab) versus CCRT followed by durvalumab in patients with unresectable stage III NSCLC. The observed adverse events of Opdivo with CCRT followed by Opdivo plus Yervoy were generally consistent with the known profiles of each component in the regimen.
- The company will complete a full evaluation of the data and work with investigators to share the results with the scientific community.